Muscular Dystrophy Treatment Market Opportunity Analysis, 2026

Nov 21
08:25

2018

Rupesh D

Rupesh D

  • Share this article on Facebook
  • Share this article on Twitter
  • Share this article on Linkedin

Rising prevalence of muscular dystrophies with unspecific current medications is expected to fuel the muscular dystrophies treatment market

mediaimage

Muscular Dystrophy is characterized by a collection of muscle-wasting conditions. The disorder is caused by genetic mutations which interfere with the production of muscle protein dystrophin,Muscular Dystrophy Treatment Market Opportunity Analysis, 2026 Articles necessary to build muscles. Muscular dystrophy is a genetic disease, consequently, the chance of an individual developing a disease increases with a history of muscular dystrophy in the family. The symptoms include shortening of muscles and tendons, the curvature of spine, weakening of heart muscles leading to cardiac problems, and breathing problems.

Click To Continue Reading on Muscular Dystrophy Treatment Market

The most common forms of muscular dystrophies include duchenne muscular dystrophy, becker muscular dystrophy, myotonic disease, congenital disease and oculopharyngeal muscular dystrophy. The cure for any form of muscular dystrophy is currently unspecified, but the symptoms can be relived through physical therapy, exercise, rehabilitative devices like a powered wheelchair, respiratory care and surgery.

According to the research conducted by the Karger Journal on 2014, the global prevalence for muscular dystrophies accounted between 19.8 and 25.1 per 100,000 person every year with myotonic dystrophy (0.5-18.1 per 100,000), duchenne muscular dystrophy (1.7-4.2) and facioscapulohumeral muscular dystrophy (3.2-4.6 per 100,000) to be the most common types of disorders.

The initial research phase of the therapies and ongoing clinical trials for the development of innovative products drives the global muscular dystrophy treatment market. Also, specific guidance for drug development for muscular dystrophy drugs published by the U.S. FDA in 2015 is expected to accelerate the new drug development for the treatment of a disorder. The emergence of disease-modifying therapies as a replacement for the unmet medical needs of patients who are not amenable to mutation-specific drugs is likely expected to fuel the revenue of the global muscular dystrophy treatment market in the forecast period. However, the fast prognosis of a disorder and low treatment seeking rate due to delayed diagnosis are the major limiting factors for the growth of global muscular dystrophy treatment market.

North America is expected to dominate the global muscular dystrophy treatment market owing to the absence of marketed pharmacological therapies indicated to treat muscular dystrophy, rising prevalence of the disease and rising research and development for producing effective drugs. Europe is expected to boost the market share in the forecast period with the growing public awareness and increasing research activities.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/914

Key Vendors:

Santhera Pharmaceuticals, PTC Therapeutics, BioMarin Pharmaceutical, Sarepta Therapeutics and Eli Lilly.

Contact Us:

Mr. ShahCoherent Market Insights1001 4th Ave, #3200Seattle, WA 98154Tel: +1-206-701-6702Email:sales@coherentmarketinsights.com

Visit our news Website: https://www.coherenttimes.org/